Korro to Participate in Upcoming Investor Conferences
Korro Bio (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, has announced its participation in two upcoming investor conferences. At the 2024 Cantor Global Healthcare Conference on September 17, COO Todd Chappell will engage in a fireside chat, while CFO Vineet Agarwal will attend investor meetings. At Chardan's 8th Annual Genetic Medicines Conference on September 30, CEO and President Ram Aiyar will participate in a fireside chat, with Agarwal also in attendance.
Both fireside chats will be webcast live and accessible through Korro's website, with replays available for 30 days post-event. These conferences provide Korro an opportunity to showcase its innovative approach to genetic medicine and engage with investors.
Korro Bio (Nasdaq: KRRO), una società biofarmaceutica che sviluppa medicinali genetici basati su editing dell'RNA, ha annunciato la sua partecipazione a due prossimi incontri per investitori. Alla 2024 Cantor Global Healthcare Conference del 17 settembre, il COO Todd Chappell parteciperà a una conversazione informale, mentre il CFO Vineet Agarwal parteciperà a incontri con gli investitori. Alla 8ª Conferenza Annuale sulle Medicine Genetiche di Chardan del 30 settembre, il CEO e Presidente Ram Aiyar prenderà parte a una conversazione informale, con Agarwal presente anche lui.
Entrambe le conversazioni informali saranno trasmesse in diretta e accessibili tramite il sito web di Korro, con le registrazioni disponibili per 30 giorni dopo l'evento. Queste conferenze offrono a Korro l'opportunità di mettere in mostra il suo approccio innovativo alla medicina genetica e interagire con gli investitori.
Korro Bio (Nasdaq: KRRO), una compañía biofarmacéutica que desarrolla medicamentos genéticos mediante edición de ARN, ha anunciado su participación en dos próximas conferencias para inversores. En la 2024 Cantor Global Healthcare Conference el 17 de septiembre, el COO Todd Chappell participará en una charla informal, mientras que el CFO Vineet Agarwal asistirá a reuniones con inversores. En la 8ª Conferencia Anual de Medicinas Genéticas de Chardan el 30 de septiembre, el CEO y Presidente Ram Aiyar participará en una charla informal, con Agarwal también presente.
Ambas charlas informales serán transmitidas en vivo y accesibles a través del sitio web de Korro, con repeticiones disponibles durante 30 días después del evento. Estas conferencias le brindan a Korro la oportunidad de demostrar su enfoque innovador en medicina genética y relacionarse con los inversores.
Korro Bio (Nasdaq: KRRO), RNA 편집 유전 의약품을 개발하는 생명공학 회사가 두 개의 다가오는 투자자 컨퍼런스에 참여한다고 발표했습니다. 9월 17일 2024 Cantor Global Healthcare Conference에서 COO Todd Chappell이 파이어사이드 채팅에 참여하며, CFO Vineet Agarwal은 투자자 회의에 참석할 예정입니다. 9월 30일 Chardan의 제8회 연례 유전 의약품 컨퍼런스에서는 CEO 겸 회장인 Ram Aiyar가 파이어사이드 채팅에 참여하고 Agarwal도 함께 참석합니다.
두 파이어사이드 채팅은 생중계되며 Korro의 웹사이트를 통해 доступ할 수 있으며, 이벤트 종료 후 30일 동안 재생할 수 있습니다. 이러한 컨퍼런스는 Korro가 유전 의학에 대한 혁신적 접근 방식을 보여주고 투자자와 소통할 수 있는 기회를 제공합니다.
Korro Bio (Nasdaq: KRRO), une société biopharmaceutique développant des médicaments génétiques par édition d'ARN, a annoncé sa participation à deux prochaines conférences pour investisseurs. Lors de la 2024 Cantor Global Healthcare Conference le 17 septembre, le COO Todd Chappell participera à une discussion informelle, tandis que le CFO Vineet Agarwal assistera à des réunions avec les investisseurs. À la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan le 30 septembre, le CEO et Président Ram Aiyar participera également à une discussion informelle, avec Agarwal également présent.
Les deux discussions informelles seront diffusées en direct et accessibles via le site web de Korro, avec des rediffusions disponibles pendant 30 jours après l'événement. Ces conférences offrent à Korro l'occasion de mettre en avant son approche innovante en matière de médecine génétique et d'interagir avec les investisseurs.
Korro Bio (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen, das RNA-bearbeitende genetische Medikamente entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Auf der 2024 Cantor Global Healthcare Conference am 17. September wird COO Todd Chappell an einem informellen Gespräch teilnehmen, während CFO Vineet Agarwal an Investorenmeetings teilnimmt. Auf der 8. Jahreskonferenz für genetische Medikamente von Chardan am 30. September wird der CEO und Präsident Ram Aiyar ebenfalls an einem informellen Gespräch teilnehmen, wobei Agarwal ebenfalls anwesend sein wird.
Beide informellen Gespräche werden live übertragen und über die Website von Korro zugänglich sein, mit Wiederholungen, die 30 Tage nach der Veranstaltung verfügbar sind. Diese Konferenzen bieten Korro die Gelegenheit, ihren innovativen Ansatz zur genetischen Medizin zu präsentieren und mit Investoren in Kontakt zu treten.
- None.
- None.
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
2024 Cantor Global Healthcare Conference
Todd Chappell, Chief Operating Officer, will participate in a fireside chat on Tuesday, September 17, 2024, at 10:55 a.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.
Chardan’s 8th Annual Genetic Medicines Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Monday, September 30, 2024, at 2:30 p.m. ET. Mr. Agarwal will also be participating at the conference.
The live webcasts of the Cantor and Chardan fireside chats can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentations, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
What investor conferences will Korro Bio (KRRO) attend in September 2024?
Who from Korro Bio (KRRO) will speak at the 2024 Cantor Global Healthcare Conference?
When is Ram Aiyar from Korro Bio (KRRO) scheduled to speak at Chardan's conference?
How can investors access Korro Bio's (KRRO) presentations at these conferences?
What type of genetic medicines is Korro Bio (KRRO) developing?
